Introduction
============

Radiotherapy (RT) is a common and indispensable method in cancer treatment, which may result in a spectrum of normal tissue side effects.[@b1-ott-11-3901] Although improvements in precise RT techniques such as three-dimensional conformal radiotherapy and intensity-modulated radiotherapy have increased the possibility of dose escalation in tumor targets,[@b2-ott-11-3901] the implementation of radiation dose is still limited by the tolerance of normal tissues in and adjacent to the irradiation field.[@b3-ott-11-3901] However, patients exhibit substantially different degrees of normal tissue toxicity even with the same treatment regimen, varying from mild to severe and occasionally lethal. Acute adverse effects may lead to unanticipated RT breaks and then remarkably affect adequate treatment delivery,[@b4-ott-11-3901],[@b5-ott-11-3901] and late adverse effects markedly influence patients' quality of life.[@b6-ott-11-3901] It is important to predict a predisposition of severe RT-induced adverse effects in normal tissues for making personal and optimized treatment decision, particularly in those with "high--intermediate risk".

The severity of RT-induced complication is associated with many factors including irradiated dose, volume of normal tissues, fractionation schedule, combined with chemotherapy, as shown by Stone et al,[@b7-ott-11-3901] but they cannot fully explain patient-to-patient differences. Recent studies indicate that genetic component may contribute to the clinical radiosensitivity and radiation adverse effects.[@b8-ott-11-3901]--[@b10-ott-11-3901] *DNA* is considered to be the main target of RT, which causes cell death by inducing base damage, single-strand breaks (SSBs), and double-strand breaks.[@b11-ott-11-3901] So, inter-individual differences in *DNA* repair capacity may determine varying degrees of the normal tissue response. Extensive researches have been conducted in order to identify some genetic markers such as single nucleotide polymorphisms (SNPs) as predictive factors for the risk of radiation-induced normal tissue toxicity.[@b10-ott-11-3901] SNPs in *DNA* damage and repair genes may alter the amino acid composition of encoded proteins, which play a role in individual's radiation response and capacity of *DNA* damage repair. The protein encoded by X-Ray Repair Cross Complementing 1 (*XRCC1*) gene, which functions in the base excision repair (BER) pathway, involves in the efficient repair of *DNA* SSBs caused by exposure to ionizing radiation.[@b12-ott-11-3901] The *XRCC1* gene is mapped at human chromosome 19q13.2--13.3. The most common variants of *XRCC1* gene are rs25487 Arg399Gln in exon 10, rs25489 Arg280His in exon 9, and rs1799782 Arg194Trp in exon 6.[@b13-ott-11-3901]--[@b15-ott-11-3901]

Although several studies have investigated the association of *XRCC1* polymorphisms with clinically observed normal tissue adverse effects, the results are not consistent. It is not sufficient to form a reliable conclusion and consequently limit their clinical applicability as biomarkers. So, we performed a systematic review to investigate these associations. This is, to our knowledge, the first comprehensive meta-analysis of genetics studies on the association between *XRCC1* polymorphisms and radiation-related adverse effects.

Materials and methods
=====================

Search strategy
---------------

A systematic literature search in PubMed, Medline (Ovid), Cochrane, Embase, Web of Science database, and the references of relevant articles was carried out to identify studies involving *XRCC1* polymorphisms and the risk of radiation-related normal tissue adverse effects (last search was updated on June 1, 2017). The search terms used were as follows: "*XRCC1* or X-Ray Repair Cross Complementing 1" in combination with "SNP or polymorphism or variant or variation or mutation or haplotype" and "radiotherapy or radiation or irradiation" and "side effect or adverse effect or complication or injury or toxicity or reaction or response or radiotoxicity or radiosensitivity or morbidity or normal tissue". All the search terms were restricted to studies in human subjects and in English language.

Inclusion criteria
------------------

Studies included in the current meta-analysis met the following inclusion criteria: 1) evaluation of the association between *XRCC1* SNPs and radiation-induced normal tissue adverse effects; 2) the design has to be a cohort study or case control study; 3) sufficient published data (genotype distributions of each groups) to estimate an odds ratio (OR) with 95% CI.

Exclusion criteria
------------------

Studies were excluded if one of the following existed: 1) data of genotype frequencies of each group were not reported and 2) case reports, reviews, editorials, and repeat studies. If there were more than one study published by the same authors based on the same populations, the one providing the most comprehensive information was included.

Data extraction
---------------

Two investigators collected the data independently in duplicate according to the inclusion criteria listed above using a standardized data extraction form. The following items were extracted from each study: first author, publication date, original country, ethnicity, cancer type, subtype of SNP in *XRCC1*, normal tissue toxicity, sample size, treatment, type of study, genotyping method, genotype number, and total number in cases and controls.

Statistical analysis
--------------------

ORs and 95% CIs were used to assess the strength of association between genetic polymorphisms and the risk of RT-induced adverse effects. The pooled OR was calculated by a fixed-effects model or a random-effects model according to the heterogeneity. Heterogeneity among eligible studies was measured by *χ*^2^-based *Q*-test and *I*^2^ statistical test.[@b16-ott-11-3901] If *Q*-test *P*\<0.1 and *I*^2^-value ≥50%,[@b16-ott-11-3901] the heterogeneity was considered statistically significant, and the assumption of homogeneity was deemed invalid and the pooled OR was calculated by random-effects model after exploring the cause of heterogeneity. Otherwise, the fixed-effects model was used. Findings of our meta-analysis are shown in forest plots. The two-tailed *P*\<0.05 was considered statistically significant. To evaluate the tolerance of different normal tissues and the occurrence time of side effects, subgroup analysis was conducted by early or late adverse effect, special types of side effects, and irradiation area. Sensitivity analysis was performed to confirm the stability and reliability of the pooled results by excluding each study individually and recalculating the pooled ORs and 95% CIs. If the number of included studies were \>10, the possible publication bias and the degree of asymmetry were examined by Begg's funnel plot and Egger's test.[@b17-ott-11-3901],[@b18-ott-11-3901] If publication bias existed, the "trim and fill" method[@b19-ott-11-3901] was used to estimate the number of missing studies and to adjust the pooled result. Statistical analysis was performed using Revman 5.3 and STATA 14.0 software.

Results
=======

Study characteristics

A total of 40 studies including 6,682 patients were eventually identified in this meta-analysis for further analysis ([Figure 1](#f1-ott-11-3901){ref-type="fig"}). The baseline characteristics of each included study are listed in [Table 1](#t1-ott-11-3901){ref-type="table"}. These studies were published from 2003 to 2017, and the sample size ranged from 34 to 579. Most of these studies included mainly Caucasian patients, and nine studies included Asian patients, of which five studies are on Chinese.[@b15-ott-11-3901],[@b20-ott-11-3901]--[@b23-ott-11-3901] The cancer categories included head and neck cancer (8 studies),[@b20-ott-11-3901],[@b21-ott-11-3901],[@b23-ott-11-3901]--[@b27-ott-11-3901] breast cancer (18 studies),[@b15-ott-11-3901],[@b28-ott-11-3901]--[@b44-ott-11-3901] prostate cancer (5 studies),[@b14-ott-11-3901],[@b45-ott-11-3901]--[@b48-ott-11-3901] cervical endometrial cancer (2 studies),[@b49-ott-11-3901],[@b50-ott-11-3901] bladder cancer (1 study),[@b51-ott-11-3901] rectal cancer (2 studies),[@b52-ott-11-3901],[@b53-ott-11-3901] non-small-cell lung cancer (NSCLC; 2 studies),[@b54-ott-11-3901],[@b55-ott-11-3901] esophageal cancer (2 studies),[@b22-ott-11-3901],[@b56-ott-11-3901] and one mixed cancers (mainly breast cancer and head and neck cancer).[@b57-ott-11-3901] Four subtypes of SNPs in *XRCC1* were analyzed in this meta-analysis. Thirty-six studies were identified for rs25487, 12 studies for rs25489, 17 studies for rs1799782, and 6 studies for rs3213245. Subgroup analyses of radiation-induced adverse effects were performed on acute or late side effects, special types of side effects, and irradiation area. The genotype distributions analyzed in each study were in Hardy--Weinberg equilibrium with *P*\>0.05. All the included eligible reports were written in English language.

Meta-analysis results
---------------------

### *XRCC1* rs25487 polymorphism

Overall, *XRCC1* rs25487 Arg399Gln G\>A polymorphism was significantly associated with acute normal tissue injury after RT. Specifically, rs25487 "Gln" allele increased the risk of acute radiation-induced adverse effects (for GA+AA versus GG, OR=1.29, 95% CI: 1.10--1.52, *P*=0.002; [Figure 2](#f2-ott-11-3901){ref-type="fig"}).

### Subgroup analysis by specific adverse effect

Because most studies investigated several different adverse effects, subgroup analysis was conducted by specific adverse effect. The results indicated that rs25487 Arg399Gln "Gln" allele carriers significantly increased acute mucositis (OR=1.91, 95% CI: 1.17--3.11, *P*=0.01) and acute gastrointestinal and genitourinary toxicity (OR=1.49, 95% CI: 1.04--2.11, *P*=0.03; [Figure 3](#f3-ott-11-3901){ref-type="fig"}). No statistically significant associations were identified between rs25487 polymorphism and any late radiation-induced adverse effects ([Figure 4](#f4-ott-11-3901){ref-type="fig"}).

### Subgroup analysis by radiotherapy area

Subgroup analysis was conducted by different irradiation area irrespective of the type of adverse effect. The rs25487 Arg399Gln polymorphism was significantly associated with a higher risk of adverse effects induced by head and neck irradiation (OR=1.46, 95% CI: 1.12--1.90, *P*=0.005), whereas the correlation was not significant for breast or pelvic irradiation (breast, OR=1.13, 95% CI: 0.95--1.33, *P*=0.18; pelvic, OR=1.20, 95% CI: 0.94--1.54, *P*=0.14, respectively; [Figure 5](#f5-ott-11-3901){ref-type="fig"}).

### *XRCC1* rs25489, rs1799782, and rs3213245 polymorphisms

Although no statistically significant associations were identified, the rs25489 Arg280His polymorphism seemed to indicate a protective effect against radiotoxicity (OR=0.78, 95% CI: 0.58--1.06, *P*=0.11), especially in acute adverse effects (OR=0.66, 95% CI: 0.38--1.14, *P*=0.14, [Figure 6](#f6-ott-11-3901){ref-type="fig"}) or in breast irradiation area (OR=0.71, 95% CI: 0.47--1.06, *P*=0.10, [Figure 7](#f7-ott-11-3901){ref-type="fig"}). No significant associations were detected between rs1799782 or rs3213245 polymorphism and RT-induced toxicity ([Figures 8](#f8-ott-11-3901){ref-type="fig"} and [9](#f9-ott-11-3901){ref-type="fig"}).

### Heterogeneity and sensitivity analyses

The heterogeneities between studies of most analyses were not significant except for three subgroup analyses, the evaluation on radiation pneumonitis of rs25487 (*I*^2^=79%, *χ*^2^ *P*=0.03), late side effect (*I*^2^=48%, *χ*^2^ *P*=0.05), and pelvic irradiation (*I*^2^=55%, *χ*^2^ *P*=0.04) of rs25489. The pooled OR calculated by random-effects model of these subgroup analyses had no statistically significant associations, and the pooled results were stable in the sensitivity analysis.

### Publication bias

The distribution of all analyzed studies for rs25487 in Begg's funnel plot was visually asymmetrical and the *P*-value of Egger's test was significantly \<0.05. However, we noticed that many included studies assessed several endpoints and different adverse effects, resulting in these studies being evaluated several times in Begg's funnel plot, which led to an inaccurate result of the publication bias. So, in order to avoid "multiple testing problem", we reevaluated the publication bias for each subgroup analysis if \>10 studies were included based on the results above in the form of one study emerged only one time. The *P*-value of Egger's test of rs25487 for RT-induced acute skin toxicity was 0.245 ([Figure 10](#f10-ott-11-3901){ref-type="fig"}), which indicates no publication bias. No publication bias was identified in other subgroup analysis of rs25487, and in rs25489, rs1799782, rs3213245 genetic models, and the *P*-values of Egger's test were all \>0.05, which suggested that there was no obvious risk of publication bias in the meta-analysis.

Discussion
==========

The protein encoded by *XRCC1* gene functions in the efficient repair of base damage and *DNA* SSBs formed by ionizing radiation and alkylating agents. This protein interacts with *DNA* ligase III, polymerase-beta, and poly (ADP-ribose) polymerase to participate in the BER pathway.[@b58-ott-11-3901] Polymorphisms in this gene are associated with varying radiosensitivity of cancer patients. Association studies on *XRCC1* genetic variations and the risk of RT-induced normal tissue injuries can help us to identify markers predicting occurrence of side effects, but previous studies reported inconsistent findings. The present meta-analysis was performed to comprehensively evaluate the influence of *XRCC1* polymorphisms on the development of radiation-induced normal tissue adverse effects. Four common SNPs of *XRCC1* were analyzed in our meta-analysis: *XRCC1* rs25487 (Arg399Gln, G\>A), *XRCC1* rs25489 (Arg280His, G\>A), *XRCC1* rs1799782 (Arg194Trp, C\>T), and *XRCC1* rs3213245 (−77 T\>C). Among these, rs25487 (Arg399Gln, G\>A) was the most commonly studied polymorphism of *XRCC1* in previous researches. Due to different molecular mechanisms of acute and late radiation effects, we analyzed the acute and late side effects separately.

To date, several systematic reviews have been published on genetic variants and normal tissue toxicities induced by radiation, most of which involved *XRCC1* polymorphism.[@b47-ott-11-3901],[@b59-ott-11-3901]--[@b63-ott-11-3901] However, due to obvious heterogeneity, it is difficult to draw any definite conclusion. So far, four meta-analyses have been published on *XRCC1* polymorphism and the risk of normal tissue injury after RT, three of which were performed only in breast cancer and one in prostate cancer patients; besides, only one to three polymorphisms have been analyzed in each paper.[@b13-ott-11-3901],[@b46-ott-11-3901],[@b64-ott-11-3901],[@b65-ott-11-3901] A positive association between rs25487 Arg399Gln polymorphism and acute side effect in breast cancer patients,[@b64-ott-11-3901],[@b65-ott-11-3901] and a negative association between rs25489 Arg280His variant and late side effect in breast cancer and prostate cancer patients[@b46-ott-11-3901],[@b65-ott-11-3901] have been reported in these meta-analyses.

In our meta-analysis, more specific evidences were provided. For rs25487 Arg399Gln polymorphism, significant associations with seriously acute adverse effects were revealed, especially acute mucositis and acute gastrointestinal and genitourinary toxicity. Subgroup analysis according to irradiated area revealed that rs25487 Arg399Gln significantly correlated with an elevated risk of side effects induced by head and neck irradiation. It indicates that patients with rs25487 variant who receive RT are more likely to experience acute adverse effects, especially in head and neck irradiation. No significant correlation with any late side effects, or with breast, pelvic, or thoracic irradiation, was observed in rs25487 polymorphism. For rs25489 Arg280His variant, inconsistent with previous results reported, no statistically significant associations were identified, but rs25489 seemed to indicate a protective effect against radiotoxicity, especially in acute adverse effects or in breast irradiation. *XRCC1* SNPs appear to be more likely to correlate with acute RT-induced side effects, but the reason is unclear. Radiation causes *DNA* strand breaks in normal cells, most of the cells die and cannot renew in time leading to acute side effects, accompanied by responses of *DNA* damage repair. Late side effects refer to the cells unable to regenerate after exhausted by radiation and eventually lead to fibrosis instead. The *XRCC1* protein functions in the efficient repair of *DNA* SSBs; thus, we speculate that *XRCC1* may participate in the *DNA* damage repair mainly in the period of RT-induced acute reactions.

No significant associations were detected between rs1799782 or rs3213245 polymorphism and RT-induced toxicity in the overall or the subgroup analyses. However, Moullan et al[@b36-ott-11-3901] and Mangoni et al[@b43-ott-11-3901] indicated that the rs1799782194Trp variant was associated with an increased risk of RT-induced adverse response when analyzed in combination with the rs25487 399Gln variant in breast cancer patients. No definite conclusion can be made for rs25489, rs1799782, or rs3213245 polymorphisms, may be due to the relatively small number of identified studies.

Although a series of studies have been made to evaluate the association between SNPs and RT-induced adverse effects, no SNPs have been thoroughly identified to have the predictive power in clinical practice. Moreover, most studies assessed the individual effect of selected SNPs,[@b59-ott-11-3901],[@b61-ott-11-3901]--[@b63-ott-11-3901] and the original researches available on combined effect of multiple SNPs are less and not enough to make a meta-analysis. Further studies are needed to elucidate the selection criteria and predictive effect for SNP combinations. In addition, genome-wide association study (GWAS) is more credible due to the comprehensive genetic coverage. Barnett et al[@b66-ott-11-3901] presented the largest GWAS in which 1217 breast cancer patients received adjuvant RT and 633 prostate cancer patients received radical RT. Quantile--quantile plot results provided evidence for the true association between common genetic variants and late toxicity, and associations with late toxicity appeared to be tumor site-specific.

The main source of heterogeneity in such meta-analysis is the overall assessment of all kinds of side effects in various cancer types. However, there are two types of RT-induced adverse effects; acute side effects can be observed during RT and within several weeks after RT, while late side effects occur months to years later.[@b3-ott-11-3901] Furthermore, different RT-induced side effects may occur in the same irradiation area, while the same type of side effect can occur in different irradiation areas with the same histological structure. Hence, it is rational to make subgroup analysis in acute or late side effects, the special type of side effects, and irradiation areas.[@b67-ott-11-3901] The subgroup analyses evaluating the effect of rs25487 on radiation pneumonitis or on thoracic irradiation yielded significant heterogeneity, because the only two identified studies on NSCLC reached contrary conclusions. The evaluations of rs25489 on late side effects and pelvic irradiation as well as rs3213245 on acute side effects also yielded significant heterogeneity. The presence of heterogeneity may be caused by the differences in study characteristics such as treatment regimen, evaluation endpoint, and genotyping method. The results are reliable because the pooled results calculated by random-effects model are stable in the sensitivity analysis.

Limitations
===========

Several limitations of the present meta-analysis should be considered. First, many included studies assessed multiple different endpoints, resulting in the same study being evaluated more than one time in one analysis. The "multiple testing problem" reduced the statistical power. Second, the number of trails in some of the subgroups and the sample sizes of some of the studies were relatively small, which also restricted the statistical power. Third, eight studies without sufficient data could not be evaluated by weight in the pooled result, which may cause some potential bias. Furthermore, data analyses were not stratified by other confounding factors such as ethnicity, genotyping method, radiation dose, or chemotherapy status because of insufficient information from the primary publications.

Conclusion
==========

The present study, to our knowledge, is the first comprehensive meta-analysis of genetics studies on the association between *XRCC1* polymorphisms and radiation-related adverse effects. In conclusion, the meta-analysis suggests that rs25487 Arg399Gln polymorphism is significantly associated with the risk of acute RT-induced adverse effects such as acute mucositis and acute gastrointestinal and genitourinary toxicity. Patients who received head and neck irradiation with rs25487 Arg399Gln polymorphism were more likely to experience RT-induced side effects. The present study also indicates a radioprotective effect for rs25489 polymorphism, especially in acute side effects or in breast irradiation, but without statistical significance. Well-designed studies with large sample size are needed to be performed to assess the value of *XRCC1* polymorphisms on radiation-induced adverse effects, which can be used clinically to identify radiosensitive patients and predict radiotoxicity.
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![Flow diagram of study search and screening for the meta-analysis.\
**Abbreviations:** RT, radiotherapy; SNP, single nucleotide polymorphism.](ott-11-3901Fig1){#f1-ott-11-3901}

![Forest plot for the association between rs25487 and radiation-induced adverse effects.\
**Notes:** A fixed-effects model was used. The square with the corresponding horizontal line represents the OR and 95% CI of each study. The area of the square reflects the weight of the study. The diamond represents the pooled OR and 95% CI. The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.\
**Abbreviations:** M--H, Mantel--Haenszel; OR, odds ratio.](ott-11-3901Fig2){#f2-ott-11-3901}

![Forest plot for the association between rs25487 and radiation-induced acute adverse effects by specific side effect.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig3){#f3-ott-11-3901}

![Forest plot for the association between rs25487 and radiation-induced late adverse effects by specific side effect.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig4){#f4-ott-11-3901}

![Forest plot for the association between rs25487 and radiation-induced adverse effects by irradiation area.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; a3-1, gastrointestinal reactions (nausea and vomiting); a3-2, gastrointestinal reactions (diarrhea, rectal pain, obstipation, bleeding and proctitis); a4, dysphagia; a5, salivary gland; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis, skin telangiectasia and breast appearance); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction; b3, radiation pneumonitis; b4, mucous membrane; b5, salivary gland.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig5){#f5-ott-11-3901}

![Forest plot for the association between rs25489 and radiation-induced adverse effects.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig6){#f6-ott-11-3901}

![Forest plot for the association between rs25489 and radiation-induced adverse effects by irradiation area.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig7){#f7-ott-11-3901}

![Forest plot for the association between rs1799782 and radiation-induced adverse effects.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a3, gastrointestinal and genitourinary toxicity; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia); b1-1, subcutaneous fibrosis; b2, gastrointestinal and genitourinary toxicity; b2-1, gastrointestinal toxicity; b2-2, genitourinary toxicity; b2-3, erectile dysfunction.\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig8){#f8-ott-11-3901}

![Forest plot for the association between rs3213245 and radiation-induced adverse effects.\
**Notes:** The "case" represents patients with severe radiation-induced side effects and "control" represents patients without or with light radiation-induced side effects. a, acute side effects; a1, skin reactions (dermatitis and erythema); a2, mucositis; a4, dysphagia; b, late side effects; b1, skin and subcutaneous reactions (subcutaneous fibrosis and skin telangiectasia).\
**Abbreviation:** M--H, Mantel--Haenszel.](ott-11-3901Fig9){#f9-ott-11-3901}

![Begg's funnel plot for the effect of rs25487 on radiation-induced skin toxicity.\
**Note:** Circles represent the actually included studies.\
**Abbreviations:** OR, odds ratio; SE, standard error.](ott-11-3901Fig10){#f10-ott-11-3901}

###### 

Baseline characteristics of the eligible studies

  Author, year                                  Country        Ethnicity   Disease                              SNP                                      Sample size (N)   Adverse effect                                                                       Assessment criteria        RT dose                                                  CT involved   Study design    Genotyping method
  --------------------------------------------- -------------- ----------- ------------------------------------ ---------------------------------------- ----------------- ------------------------------------------------------------------------------------ -------------------------- -------------------------------------------------------- ------------- --------------- ----------------------------------------
  Alsbeih et al,[@b24-ott-11-3901] 2010         Saudi Arabia   Caucasian   NPC                                  rs25487                                  60                Late: fibrosis                                                                       RTOG/EORTC ≥G2             66--70 Gy                                                Yes           Case--control   PCR
  Andreassen et al,[@b29-ott-11-3901] 2003      Denmark        Caucasian   Breast                               rs25487                                  41                Late: fibrosis                                                                       LENT-SOMA ≥G3              36.6--51.4 Gy                                            No            Cohort          PCR
  Andreassen,[@b63-ott-11-3901] 2005            Denmark UK     Caucasian   Breast                               rs25487                                  52                Late: breast appearance                                                              Photographic ≥G2           50 Gy/25f, 42.9 Gy/13f, 39 Gy/13f                        NA            Case--control   PCR
  Andreassen et al,[@b30-ott-11-3901] 2006      Denmark        Caucasian   Breast                               rs25487, rs25489, rs1799782              120               Late: fibrosis                                                                       LENT-SOMA ≥G3              41 Gy                                                    Yes           Cohort          PCR
  Azria et al,[@b57-ott-11-3901] 2008           France         Caucasian   Breast, HNC                          rs25489                                  34                Late: fibrosis                                                                       RTOG/EORTC CTC v3.0 ≥G3    NA                                                       Yes           Case--control   PCR
  Brem et al,[@b31-ott-11-3901] 2006            France         Caucasian   Breast                               rs3213245                                247               Acute and Late                                                                       EORTC                      50 Gy, tumor bed boost 10 Gy                             NA            Case--control   PCR-RFLP
  Burri et al,[@b14-ott-11-3901] 2008           America        Mixed       Prostate                             rs25487, rs25489, rs1799782              135               Late: rectal bleeding, urinary morbidity, erectile dysfunction                       RTOG/EORTC ≥G2             125I: 160 Gy 103 Pd: 124 Gy 103 Pd: 100 Gy+EBRT: 45 Gy   NA            Cohort          PCR
  Changclaude et al,[@b33-ott-11-3901] 2005     Germany        Caucasian   Breast                               rs25487, rs25489, rs1799782              446               Acute: skin reaction                                                                 CTCAE v2.0 ≥G2c            Mean 54.0±4.8 Gy (35.5--64.5 Gy)                         No            Cohort          PCR-RFLP
  Changclaude et al,[@b32-ott-11-3901] 2009     Germany        Caucasian   Breast                               rs25487, rs25489, rs1799782, rs3213245   409               Late: telangiectasia                                                                 RTOG/EORTC LENT-SOMA ≥G2   Mean 61.8±4.10 Gy (51--71 Gy)                            No            Cohort          PCR-RFLP
  Cheuk et al,[@b20-ott-11-3901] 2014           Hong Kong      Asian       NPC                                  rs25487, rs1799782                       120               Late: fibrosis                                                                       RTOG ≥G1                   66--76 Gy                                                Yes           Cohort          PCR-RFLP
  Damaraju et al,[@b45-ott-11-3901] 2006        Canada         Mixed       Prostate                             rs25489, rs1799782                       83                Late: bladder or rectal toxicity                                                     RTOG ≥G2                   Mean 77.1 Gy (68.3--82.1 Gy)                             No            Cohort          PCR
  De Ruyck et al,[@b49-ott-11-3901] 2005        Belgium        Caucasian   Cervical, endometria                 rs25487, rs25489, rs1799782              62                Late                                                                                 CTCAE v3.0 ≥G2             EBRT: 45--66 Gy 192I: 15--35 Gy                          Yes           Cohort          PCR-RFLP
  De Ruyck et al,[@b25-ott-11-3901] 2013        Belgium        Caucasian   HNC                                  rs3213245                                189               Acute: dysphagia                                                                     CTCAE v3.0 ≥G3             66--70 Gy                                                Yes           Cohort          PCR-RFLP
  Duldulao et al,[@b52-ott-11-3901] 2013        USA            Caucasian   Rectal                               rs25487                                  132               Acute: gastrointestinal toxicity                                                     CTCAE v3.0 ≥G3             NA                                                       Yes           Cohort          PCR, direct sanger sequencing
  Falvo et al,[@b42-ott-11-3901] 2011           Italy          Caucasian   Breast                               rs1799782                                57                Acute: erythema                                                                      CTCAE v3.0 ≥G1             21 Gy/f                                                  Yes           Cohort          PCR
  Falvo et al,[@b34-ott-11-3901] 2012           Italy          Caucasian   Breast                               rs25487                                  57                Late: fibrosis, fat necrosis                                                         CTCAE v3.0 ≥G2             21 Gy/f                                                  Yes           Cohort          PCR
  Giotopoulos et al,[@b35-ott-11-3901] 2007     UK             Mixed       Breast                               rs25487                                  167               Late: telangiectasia                                                                 RTOG LENT-SOMA ≥G2         40--50 Gy, tumor bed boost of 15 Gy/5f                   Yes           Cohort          PCR-RFLP
  Ishikawa et al,[@b50-ott-11-3901] 2011        Japan          Asian       Cervical                             rs25487                                  208               Acute: diarrhea                                                                      CTCAE v2.0 ≥G2             EBRT 50.6 Gy Brachytherapy 24.0 Gy                       Yes           Cohort          PCR
  Langsenlehner et al,[@b46-ott-11-3901] 2011   Austria        Caucasian   Prostate                             rs25487, rs25489, rs1799782              579               Late: bladder or rectal toxicity                                                     RTOG/EORTC ≥G2             66--70.4 Gy                                              No            Cohort          PCR
  Li et al,[@b21-ott-11-3901] 2013              China          Asian       NPC                                  rs25487, rs1799782                       114               Acute: mucositis, dermatitis                                                         CTCAE v3.0 ≥G3             50--70 Gy                                                Yes           Cohort          PCR-RFLP
  Mangoni et al,[@b43-ott-11-3901] 2011         Italy          Caucasian   Breast                               rs25487, rs1799782                       87                Acute: skin reaction                                                                 CTCAE v2.0 ≥G2c            50 Gy/25f, 44 Gy/16f                                     Yes           Cohort          PCR
  Moullan et al,[@b36-ott-11-3901] 2003         France         Caucasian   Breast                               rs25487, rs25489, rs1799782              254               Acute and Late                                                                       EORTC                      50 Gy, tumor bed boost 10 Gy                             NA            Cohort          PCR
  Mumbrekar et al,[@b37-ott-11-3901] 2017       India          Asian       Breast                               rs25487                                  126               Acute: skin reaction                                                                 RTOG ≥G2                   50 Gy, tumor bed boost 10 Gy for 26 patients             Yes           Cohort          PCR
  Popanda et al,[@b47-ott-11-3901] 2009         Germany        Caucasian   Prostate                             rs25487, rs25489, rs1799782              405               Acute: proctitis cystitis                                                            CTCAE v2.0 ≥G3             61--72 Gy                                                No            Cohort          Sequence-specific hybridization probes
  Pratesi et al,[@b26-ott-11-3901] 2011         Italy          Caucasian   HNC                                  rs25487                                  101               Acute: mucositis, skin erythema                                                      CTCAE v3.0 ≥G2             Mean 62 Gy (54--70 Gy)                                   Yes           Case--control   PCR-RFLP
  Raabe et al,[@b44-ott-11-3901] 2012           Germany        Caucasian   Breast                               rs25487                                  83                Acute: erythema                                                                      RTOG ≥G2                   50--50.4 Gy                                              NA            Cohort          PCR-RFLP, MALDI-TOF
  Sakano et al,[@b51-ott-11-3901] 2010          Japan          Asian       Bladder                              rs25487                                  95                Acute: gastrointestinal toxicity                                                     CTCAE v3.0 ≥G2             Median 48.6 Gy (30.0--60.4 Gy)                           Yes           Cohort          PCR-RFLP
  Smith et al,[@b53-ott-11-3901] 2017           America        Mixed       Rectal                               rs25487                                  165               Acute: gastrointestinal and genitourinary toxicity (diarrhea, proctitis, cystitis)   CTCAE v3.0 ≥G3             Median 50.4 Gy                                           Yes           Cohort          PCR, MALDI-TOF
  Suga et al,[@b38-ott-11-3901] 2007            Japan          Asian       Breast                               rs25487                                  399               Acute: skin reaction                                                                 CTCAE v2.0 ≥G2             46--60 Gy                                                Yes           Cohort          PCR
  Terrazzino et al,[@b39-ott-11-3901] 2012      Italy          Caucasian   Breast                               rs25487, rs1799782, rs3213245            286               Acute: skin reaction                                                                 RTOG ≥G2                   50--50.4 Gy, tumor bed boost 9--16 Gy                    Yes           Cohort          PCR-RFLP
  Terrazzino et al,[@b40-ott-11-3901] 2012      Italy          Caucasian   Breast                               rs25487, rs1799782                       237               Late: fibrosis                                                                       LENT-SOMA ≥G2              50--50.4 Gy, tumor bed boost 9--16 Gy                    Yes           Cohort          PCR-RFLP
  Tucker et al,[@b54-ott-11-3901] 2013          USA            Caucasian   NSCLC                                rs25487                                  141               Late: radiation pneumonitis                                                          CTCAE v3.0 ≥G3             Median 63 Gy (50.4--72 Gy)                               Yes           Cohort          PCR-RFLP
  Usmani et al,[@b48-ott-11-3901] 2014          Canada         Caucasian   Prostate                             rs25487                                  217               Late: urinary toxicity                                                               RTOG ≥G2                   125I ≥145 Gy                                             No            Cohort          PCR
  Venkatesh et al,[@b27-ott-11-3901] 2014       India          Caucasian   HNC                                  rs25487, rs25489, rs1799782, rs3213245   183               Acute: mucositis, skin reaction                                                      RTOG ≥G3                   60--70 Gy                                                Yes           Cohort          PCR-RFLP
  Yin et al,[@b55-ott-11-3901] 2011             USA            Mixed       NSCLC                                rs25487                                  165               Late: radiation pneumonitis                                                          CTCAE v3.0 ≥G2             Median 63 Gy (50.4--84.0 Gy)                             Yes           Cohort          PCR-RFLP
  Yoon et al,[@b56-ott-11-3901] 2011            USA            Mixed       Esophageal adenocarcinoma            rs25487                                  60                Acute: dysphagia                                                                     CTCAE v2.0 ≥G3             45 Gy                                                    Yes           Cohort          PCR, MALDI-TOF
  Xian et al,[@b22-ott-11-3901] 2015            China          Asian       Esophageal squamous cell carcinoma   rs25487                                  118               Acute: esophagitis                                                                   CTCAE ≥G3                  Median 60 Gy (45--66 Gy)                                 Yes           Cohort          PCR
  Zhai et al,[@b23-ott-11-3901] 2016            China          Asian       NPC                                  rs25487                                  60                Acute and Late: skin, mucosa, salivary gland                                         RTOG ≥G2                   66--76 Gy                                                Yes           Cohort          PCR-LDR
  Zhou et al,[@b15-ott-11-3901] 2010            China          Asian       Breast                               rs25487, rs25489, rs1799782, rs3213245   119               Acute: skin reaction                                                                 CTCAE v3.0 ≥G2             46--54 Gy                                                No            Cohort          PCR-RFLP
  Zschenker et al,[@b41-ott-11-3901] 2010       Germany        Caucasian   Breast                               rs25487                                  69                Late: fibrosis                                                                       LENT-SOMA ≥G2              54--55 Gy                                                Yes           Cohort          PCR-RFLP, MALDI-TOF

**Abbreviations:** CT, chemotherapy; CTC, Common Toxicity Criteria; CTCAE, Common Terminology Criteria for Adverse Events; EBRT, external beam radiation therapy; EORTC, European Organization for Research and Treatment of Cancer; HNC, head and neck cancer; LDR, ligase detection reaction; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; LENT-SOMA, Late Effects of Normal Tissue-Subjective Objective Management Analytical; NA, not available; NPC, nasopharyngeal carcinoma; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; SNP, single nucleotide polymorphism.
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